The safety profile was consistent with known immunotherapy toxicities, including hyponatremia (13.3%), thrombocytopenia (20%), neutropenia (46.7%), and elevated ALT (6.7%) [8,10,11]. This evidence concerns the gene GPT and Hyponatremia.